← Back to Search

Behavioural Intervention

Transcranial Magnetic Stimulation for Substance Addiction

N/A
Waitlist Available
Led By Ryan Carnahan, PharmD, MS
Research Sponsored by University of Iowa
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosed with an active methamphetamine use disorder
Is engaged in psychosocial treatment or articulates a plan to engage in psychosocial treatment for methamphetamine use disorder during the study period
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 1 week, 2 weeks, 3 weeks, 4 weeks, 8 weeks, 12 weeks
Awards & highlights

Study Summary

This trial is testing a new transcranial magnetic stimulation (TMS) treatment for methamphetamine use disorder (MUD). TMS is a noninvasive brain stimulation technique that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of MUD. The study will test if this new TMS treatment can help reduce methamphetamine use, craving, and improve quality of life in people with MUD.

Eligible Conditions
  • Stimulant Addiction
  • Methamphetamine Addiction
  • Substance Addiction

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 1 week, 2 weeks, 3 weeks, 4 weeks, 8 weeks, 12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 1 week, 2 weeks, 3 weeks, 4 weeks, 8 weeks, 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Retention in psychosocial treatment
Retention in the study
Secondary outcome measures
Assessment of Recovery Capital
Brief Addiction Monitor Protective Factors Subscale
Brief Addiction Monitor Risk Factors Subscale
+18 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: MPFC firstExperimental Treatment1 Intervention
Participants in this arm will undergo all study procedures including consent; pre-, during, and post-psychological assessments; pre- and post- MRI and fMRI; 16 treatments of dual target TMS over a 4-week period; and substance use-related assessments to include substance use, withdrawal symptoms, and cravings to use. This arm will receive the medial prefrontal cortex stimulation first.
Group II: DPFC firstExperimental Treatment1 Intervention
Participants in this arm will undergo all study procedures including consent; pre-, during, and post-psychological assessments; pre- and post- MRI and fMRI; 16 treatments of dual target TMS over a 4-week period; and substance use-related assessments to include substance use, withdrawal symptoms, and cravings to use. This arm will receive the dorsolateral prefrontal cortex stimulation first.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Transcranial Magnetic Stimulation
2011
Completed Phase 4
~710

Find a Location

Who is running the clinical trial?

University of New MexicoOTHER
371 Previous Clinical Trials
3,529,022 Total Patients Enrolled
University of UtahOTHER
1,088 Previous Clinical Trials
1,728,330 Total Patients Enrolled
University of IowaLead Sponsor
443 Previous Clinical Trials
878,671 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this trial currently accepting new participants?

"Clinicaltrials.gov reports this trial is no longer enrolling, after being initially posted on October 6th 2020 and most recently updated on May 19th 2022. Nevertheless, more than 400 other trials are actively recruiting patients currently."

Answered by AI

Is this research endeavor limited to adults under 40 years of age?

"This medical research is enrolling participants aged 18 and younger than 60."

Answered by AI

Am I qualified to join in this experiment?

"Patients with a history of substance abuse within the age range of 18 to 60 are eligible for enrolment in this clinical trial, which is seeking 20 participants."

Answered by AI

What are the primary objectives of this clinical experiment?

"This medical trial, lasting for 12 weeks and monitored at baseline, is focused on retaining psychosocial treatment. The secondary outcomes include the Difficulties in Emotion Regulation Scale--Short Form (ranging from 18 to 90 with higher values indicating more difficulty with emotional regulation), Brief Addiction Monitor Use Subscale (scores ranging from 0 to 12, where a greater score suggests increased usage) as well as UPPS-P Impulsive Behavior Scale (which yields scores between 0 and 48 that reflect impulsivity)."

Answered by AI
Recent research and studies
~4 spots leftby Mar 2025